PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Cancer
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histological/cytological diagnosis of de novo adenocarcinoma of the pancreas 2) Amendable & assigned by the investigator to receive therapy with gemcitabine & nab-paclitaxel

You may not be eligible for this study if the following are true:

  • 1) Prior palliative treatment (e.g. surgery, radiation) to the tumor 2) Cancer requiring anti-tumor treatment within the 5 years before inclusion, excluding treated stage I prostate cancer, in situ cervical or uterus cancer, in situ breast cancer and non-melanomatous skin cancer. 3) Concurrent anti-tumor therapy beyond gemcitabine and nab-paclitaxel 4) Implantable electronic medical devices in the torso, such as pacemakers

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.